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ValidationAbstract The study is focused to develop and validate a UV-Spectrophotometric and Densitom-
etry method for simultaneous estimation of Irinotecan from their dosage form. Based on spectro-
photometric characteristic of method are described for the simultaneous determination of
Irinotecan HCl, at 247 nm for simple UV spectrum and at 268 nm for derivative spectrum was
found adequate for quantiﬁcation. The method was validated for linearity, accuracy, precision,
reproducibility, and speciﬁcity as per International Conference on Harmonization guidelines. The
linearity signal and concentration of Irinotecan in the range of 2–10 lg/ml in aqueous solution pres-
ent a correlation coefﬁcient (r2) of 0.9999 for simple UV and 0.9997 for ﬁrst order derivative spec-
trum. Second method is the high performance thin layer chromatographic (HPTLC) separation
followed by densitometric measurements on normal phase silica gel 60F254. The chromatographic
separation was carried out on precoated silica gel 60F254 aluminium plates using a mixture of tol-
uene/ethyl acetate/methanol/carbon tetrachloride, in the volume ratio of 9.2:5:0.9:0.8 (v/v/v/v)
respectively as mobile phase. Densitometric analysis was carried out at 317 nm. The linear regres-
sion analysis data showed good linear relationship in the concentration range of 200–1200 (ng/
band) for Irinotecan. The limits of quantitation for Irinotecan were 34 (ng/band). The limit of
detection (LOD) and limit of quantitation (LOQ) were 36 and 57 ng/spot, respectively. The drug
was satisfactorily resolved with Rf value 0.34 ± 0.08. The accuracy and repeatability of the
proposed method were ascertained by evaluating various validation parameters like linearity
(200–1200 ng/spot). The method was found to be rapid, speciﬁc, precise and accurate and can be
successfully applied for the routine analysis of Irinotecan bulk and marketed dosage form.
ª 2012 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Irinotecan HCl (Fig. 1) (7-ethyl-10-[4-(l-piperidino)-1-piperidi-
no]carbonyloxy camptothecin; CPT-11), a semisynthetic
water-soluble derivative of camptothecin, an alkaloid isolated
from Camptotheca acuminata, has unique antitumor activity,
preventing DNA synthesis by inhibiting topoisomerase I. Iri-
notecan-HCl is a new drug which has antitumor activity in a
wide range of malignancies, such as metastatic colorectal can-
cer, upper gastrointestinal, pancreatic, lung and breast cancer,
and gynaecological malignancies (Chollet et al., 1998; Hwang
et al., 2003). Camptothecin is an alkaloid extracted from a
plant known as C. acuminata belonging to the family Nyssa-
ceae (Sawada et al., 1991; Kawato et al., 1991). Irinotecan
(Budavari, 2001; Kono and Hara, 1991; Poujol et al., 2003;
De et al., 2003) inhibits the action of enzyme topoisomerase
I which produces reversible single strand breaks in DNA dur-
ing DNA replication in tumor growth. Irinotecan hydrochlo-
ride is a pale yellow to yellow crystalline powder, with the
empirical formula C33H38N4O6ÆHClÆ3H2O and molecular
weight of 677.19. It is slightly soluble in water and organic sol-
vents. Literature survey reveals many Chromatographic meth-
ods for the determination of Irinotecan in biological ﬂuids like
plasma, blood and urine (Shende and Gaud, 2009; Murali
et al., 2007; Yang et al., 2005; Owens et al., 2003; Hang
et al., 2009; Baylatry et al., 2010; Rivory and Robert,1994; Ed-
mond et al., 2005). In the present research work an accurate
and economical UV Spectrophotometric and TLC Densito-
metric method has been developed for the estimation of Irino-
tecan in formulation and bulk drug substances.
2. Materials and method
2.1. UV spectrophotometric method
UV–Visible double beam spectrophotometer, Shimadzu mod-
el-1700 having spectral bandwidth 3 nm and of wavelength
accuracy ±1 nm, with 1 cm quartz cells was used. All other
chemicals and reagents used were of analytical grade and were
purchased from Merck Chemicals Corporation Ltd., Mumbai,
India. Deionized and ultrapure water used in all experiments
was obtained from Milli-Q system (Millipore). Silica gel
60F254 TLC plates (20 · 10 cm & 10 · 10 cm, layer thickness
0.2 mm, Merck, Germany) were used as stationary phase.
The injection formulation available in Indian market under
the trade name of ‘‘Irinocam’’ of 5 ml (100 mg) per vial, man-N
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O
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Figure 1 Structure oufactured by Dr. Reddy’s Laboratories, Hyderabad, India.
Solubility of the drug was checked in solvents like water, meth-
anol, DMSO.
The spectra of drugs in this solution were recorded. Absor-
bance of drug exhibited distinct kmax in water. Hence water
was selected as a solvent for further studies. However, the drug
is freely soluble in water hence water was chosen as a solvent
for developing the method and the cost of water is low as com-
pared to the other solvents.
2.1.1. Preparation of stock solution
Weigh and transfer accurately, equivalent to 100 mg of Irino-
tecan as working standard into 100 ml volumetric ﬂask, dis-
solve and dilute up to mark with distilled water. Transfer
10 ml solution from the stock to 100 ml volumetric ﬂask with
distilled water to produce a concentration of 100 lg/ml, use
this as standard stock solution.
2.1.2. Preparation of working standard solution
Weigh accurately 100 mg of Irinotecan, transfer to a 100 ml
volumetric ﬂask, and make up to volume with water and ﬁlter.
Take 10 ml from that solution to 100 ml volumetric ﬂask and
make up the volume to 100 ml with distilled water. From the
stock solution different concentrations of Irinotecan, were pre-
pared and scanned in UV region at 200–400 nm. The wave-
length corresponding to maximum absorbance (kmax) was
found at 268 nm (Fig. 2).
2.1.3. Preparations of sample solution
Ten injection vials were weighed and mixed properly. A quan-
tity equivalent to 100 mg of Irinotecan was weighed into
100 ml volumetric ﬂask. To this ﬂask, 20 ml distilled water
was added and sonicated for 5 min with continuous shaking,
the solution was cooled to ambient temperature and diluted
up to mark with the same solvent. The solution was then ﬁl-
tered through Whattman ﬁlter paper No. 41. From the ﬁltrate,
appropriate dilutions were made in distilled water to obtain the
desired concentration of 10 lg/ml. Measure the absorbance at
341 nm of standard and sample solution of same concentration
and calculate the percent purity of sample. From the stock
solution (100 lg/ml), working standard solutions of drugs were
prepared by appropriate dilution and were scanned in entire
UV range to determine the kmax. Standard solutions were pre-
pared having concentration 2–10 lg/ml for Irinotecan. The
absorbance of these standard solutions was measured at
341 nm.N
N
O
O
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.HCl .3H2O
f Irinotecan HCl.
Figure 2 UV spectra Irinotecan HCl.
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The instrument used in the present study was Camag HPTLC
system comprising Camag Linomat V automatic sample appli-
cator, Hamilton syringe (100 ll), and Camag TLC scanner III
with Wincats software. The HPTLC system consisted of Lin-
omat V auto sprayer connected to a nitrogen cylinder, a twin
trough glass chamber (10 · 10 cm), saturated with ﬁlter paper
for 30 min. Separation was performed as stationary phase and
using a mobile phase comprising of toluene/ethyl acetate/
methanol/carbon tetrachloride, in the volume ratio of
9.2:5:0.9:0.8 (v/v/v/v) respectively. After development, plates
were observed under UV light. Scanning wavelength for
Irinotecan was 317 nm. High performance thin layer chroma-
tography was performed on 10 · 10 cm precoated silica gel
60F254 precoated plates from E. Merck. The adsorbent has a
very large surface area; it may absorb air and other impurities
from atmosphere, particularly volatile impurities, after the
pack has been opened. The non-volatile impurities adsorbed
by layer can lead to irregular baseline in scanning densitome-
try. To avoid possible interference from such impurities in
quantitative analysis, plates were prewashed with methanol,
dried, and activated for 30 min at 135 C with the plates being
placed between two sheets of glass to prevent deformation of
aluminium during heating.
3.1. Preparation of standard solution
A stock solution of drug was prepared by dissolving 100 mg of
pure Irinotecan in a 100 ml volumetric ﬂasks containing sufﬁ-
cient amount of methanol to dissolve the drug, sonicated for
about 15 min and then made up to volume with methanol
(1 mg/ml). A standard solution was prepared by dilution of
the stock solution with methanol to give a concentration of
100 lg/ml. Further dilutions were made with methanol to give
a solution in concentration range of 200–1200 ng/ml.
3.2. Preparations of sample solution and application
Ten injection vials were weighed and mixed properly. A quan-
tity equivalent to 100 mg of Irinotecan was weighed into
100 ml volumetric ﬂask. To this ﬂask, 20 ml distilled water
was added and sonicated for 5 min with continuous shaking,
the solution was cooled to ambient temperature and diluted
up to mark with the same solvent. The solution was then ﬁltered
throughWhattman ﬁlter paperNo. 41. From the ﬁltrate, appro-priate dilutions were made in distilled water to obtain the de-
sired concentration of 10 lg/ml. On the HPTLC plates spots
of the standard and sample were applied. The plates were devel-
oped and after development the bands of the drugs were
scanned at 317 nm. The peak height and area of the standard
and sample bands were compared to obtain the concentration.
A solution of Irinotecan (1 mg/ml) was prepared. This solution
was further diluted with methanol to yield a solution containing
1 lg/ml. Different concentrations of Irinotecan in a concentra-
tion range of 200–1200 ng/ml were applied on plates as 8 mm
bands, 8 mm apart and 1 cm from edge of the plate, by means
of Camag Linomat V automatic sample applicator ﬁtted with
100 ll Hamilton syringe. A methanol blank was applied to par-
allel track. The mobile phase, toluene/ethyl acetate/methanol/
carbon tetrachloride, in the volume ratio of 9.2:5:0.9:0.8 (v/v/
v/v) respectively was poured into the twin trough glass chamber
and the glass chamber left to equilibrate for 30 min at
35 ± 40 C. After that the plate was placed in Camag twin
trough glass chamber. After development, the plate was re-
moved from the chamber, dried in current of hot air, and
scanned at 317 nm, using a deuterium lamp, bymeans of Camag
TLC scanner III densitometer. The Wincats software was used
for data acquisition and processing of the plate.
3.3. Linearity of detector response
A stock solution of drug was prepared by dissolving 100 mg of
pure Irinotecan in a 100 ml volumetric ﬂasks containing sufﬁ-
cient amount of methanol to dissolve the drug, sonicated for
about 15 min and then made up to volume with methanol
(1 mg/ml). A standard solution was prepared by dilution of
the stock solution with methanol to give a concentration of
100 lg/ml. Further dilutions were made with methanol to give
a solution in concentration range of 200–1200 ng/ml of Irino-
tecan were spotted as sharp bands on the precoated TLC plate,
using Camag Linomat IV semiautomatic applicator under
nitrogen stream.
4. Validation of method
The method was validated as per the ICH (ICH, 2002) in terms
of linearity, accuracy and speciﬁcity, intra-day and inter-day
precision, repeatability of measurement of peak area as well
as repeatability of sample application. To spectrophotometric
study the accuracy and precision of the above proposed meth-
ods, recovery studies were carried out by the addition of known
amount of standard drug solutions of Irinotecan preanalysed
solution. The resulting solution was then analyzed by proposed
methods. Results of recovery studies were found to be satisfac-
tory and are reported in Tables 2 and 3. TLC Densitometry lin-
earity was studied in the concentration range, aliquots of
standard stock solution of Irinotecan (100 ng/ll were applied
on the TLC plate under nitrogen stream. TLC plates were devel-
oped under above established conditions. Area under peak was
recorded and plotted against concentration. The speciﬁcity of
the method was ascertained by analyzing standard drug and
sample. The spot for drug was conﬁrmed by comparing the Rf
and spectra of the sample spots with those of standard drug.
To check the accuracy of the method, recovery studies were car-
ried out by the addition of standard drug solution to pre-ana-
lyzed sample solution at three different levels 80%, 100% and
Table 1 Analysis data of tablet formulations.
S. No. Parameters UV Spectrophotometry HPTLC
1. Label claim 5 ml Vial (100 mg) 5 ml Vial (100 mg)
2. Drug content 99.97 100.07
3. ±S.D. 0.47 0.18
4. %R.S.D. 0.30 0.23
Table 2 Recovery studies of Irinotecan HCl.
Label
claim (ml)
Irinotecan HCl
Method Excess drug
added to the
analyte (%)
Amount
recovered (ng)
% Recovery
5 UV 80 5.01 100.04
100 4.98 98.08
120 5.10 101.03
5 HPTLC 80 4.97 99.97
100 5.02 100.02
120 5.17 101.07
Table 3 Summary of repeatability, precision and ruggedness.
Parameter UV HPTLC
Repeatability 0.96 0.86
(a) Intra-day 1.21 0.41–1.09
(b) Inter-day 1.04 0.45–1.24
Rf – 0.34 ± 0.08
Linearity and range (ng/spot) – 400–1600 ng/spot
Linearity detection (ng/spot) – 7.8 ng/spot
Limit of quantitation (ng/spot) – 34 ng/spot
Repeatability 0.29 0.73
LOD 0.935 36
LOQ 1.173 57
% Accuracy ± S.D.a (n= 6) 100.05%± 0.3 99.96%± 0.04
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noted. At each level of the amount, three determinations were
carried out (Table 2). The intra-day precision was determined
by analyzing standard solutions of Irinotecan in range of 200–
1200 ng/band for three times on the same day while inter-day
precision was determined by analyzing corresponding stan-
dards on three different days over a period of one week (Table
3). Robustness studies were carried out by examining the effect
of small, deliberate variation of the analytical conditions on the
peak areas of the drug. Factors varied were volume of mobile
phase (±0.5%), and time from application to development (0,
10, 20, and 30 min) and from development to scanning (0, 30,
60, and 90 min). One factor at a time was changed to study
the effect. The robustness of the method was checked at amount
of 800 ng/band. The limit of detection (LOD) and limit of quan-
titation (LOQ) were determined on the basis of signal to noise
ratio. LOD was the amount of the applied sample producing
a peak area that is equal to the sum of the mean blank area
and three times the standard deviation. LOQ was the amount
of the applied sample producing a peak area that is equal to
the sum of the mean blank area and ten times its standard devi-
ation. Stock solution of Irinotecan was prepared and different
volumes of stock solution in the range of 200–1200 ng/band
were spotted in triplicate. The amount Irinotecan by spot versus
average response (peak area) was graphed and the equation for
this was determined. The standard deviations (S.D.) of re-
sponses were calculated. The average of standard deviations
was calculated (A.S.D.). Detection limit was calculated by
(3.3 · A.S.D.)/b and quantiﬁcation limit was calculated by
(10 · A.S.D.)/b, where ‘‘b’’ corresponds to the slope obtained
in the linearity study of method (Table 3).
5. Results and discussion
UV Spectrophotometric and HPTLC methods were found to
be accurate, economic and rapid for routine simultaneous esti-
mation of Irinotecan, in bulk and formulation dosage forms.
For UV Spectrophotometric method, linearity was obtained
in concentration range of 10–50 lg/ml, for both the drugs;
with regression 0.9998 intercept 0.01876 and 0.02843 and
slope 0.09661 Irinotecan, respectively. Standard stock solution
was suitably diluted with distilled water to obtain concentra-
tion ranging from 2–10 lg/ml. Absorbance of these solutions
was measured at 268 nm. Analysis of formulation is described
in Table 1, the regression equation and correlation coefﬁcient
were found to be Y= 1.2653 · 0.327 and 0.9994 respec-
tively. The relative standard deviation values are below 2%
indicating the precision of the method. The validations of
the proposed methods were further conﬁrmed by recovery
studies. The % recovery vary from 99.14 ± 0.043 to
101.31 ± 0.05, indicating good accuracy of methods. The high
% recovery value indicates non interference from excipients
used in formulations.
The speciﬁc range derived from the linearity studies: The
range was calculated from the linearity graph. From the lower
to higher concentration between which the response is linear,
accurate and precise. Acceptance criteria: R.S.D. < 2.0. The
range for Irinotecan was found to be 200–1200 ng/ml. Use of
pre-coated silica gel HPTLC plates with toluene/ethyl ace-
tate/methanol/carbon tetrachloride, in the volume ratio of
9.2:5:0.9:0.8 (v/v/v) resulted in good separation of the drug.Six different concentrations of mixture of Irinotecan were pre-
pared from stock solution of Irinotecan (100 lg/ml). The drug
peak-area was calculated for each concentration level and a
graph was plotted of drug concentration against the peak area.
The plot was linear for Irinotecan in the concentration range
of 10–100 lg/spot. The limit of detection (LOD) was found
to be 36 ng/spot for Irinotecan. Limit of quantitation (LOQ)
for Irinotecan was determined experimentally by spotting six
replicates of each drug at LOQ concentration. The LOQ of
was found to be 57 ng/spot. A representative calibration curve
was obtained by plotting peak area of compound against the
concentration over the range of 200–1200 ng/spot. The drug
was satisfactorily resolved with Rf value 0.34 ± 0.08. The drug
content was found to be 101.09 with a R.S.D.% of 0.38. The
low values of R.S.D.% indicated the suitability of this method
for routine analysis of Irinotecan in pharmaceutical dosage
forms. The intra-day and inter-day relative standard devia-
tions were found in the range 0.41–1.09% and 0.45–1.24%
respectively. Repeatability of sample application and measure-
ment of peak area were carried out using six replicates of same
spot (800 ng/spot of Irinotecan). The intra-day and inter-day
variation for the Irinotecan was carried out at three different
concentration levels of about 200, 800 and 1200 ng/spot.
S1372 S. Sharma, M.C. SharmaThe smaller values of intraday and inter-day variation in the
analysis indicate that the method is precise. R.S.D. for repeat-
ability of measurement of peak area and repeatability of sam-
ple application was found to be 0.674% and 1.876%,
respectively. To ascertain its effectiveness, system suitability
tests were carried out on freshly prepared stock solutions.
6. Conclusion
The UV and HPTLC methods developed in this study have the
advantage of simplicity, precision, accuracy, and convenience.
It is of potential value for the analysis of Irinotecan as the bulk
drug and in commercial formulations. The developed and val-
idated RP- TLC technique is precise, speciﬁc and accurate
indicating for the determination of drug. Statistical analysis
proves that the method is reproducible and selective for the
analysis of Irinotecan as bulk drug and formulations. The ma-
jor advantage of HPTLC is that several samples can be run
simultaneously using a small quantity of mobile phase –unlike
HPLC – thus reducing the analysis time and cost per analysis.Acknowledgements
We are grateful to Prof. D.V. Kohli and Prof. A.K. Singhai,
Department of Pharmaceutical Sciences, Dr. Hari Singh, Gour
University, Sagar (M.P.), India, for providing facility and
valuable suggestions.
References
Baylatry, M.T., Joly, A.C., Pelage, J.P., 2010. J. Chromatogr. B
Analyt. Technol. Biomed. Life Sci. 878 (9–10), 738–742.Budavari, S. (Ed.), 2001. The Merck Index, thirteenth ed. Merck & Co.
Inc., White house Station, NJ, 5109.
Chollet, D.F., Goumaz, L., Renard, A., 1998. J. Chromatogr. B 718,
163–175.
De, J.F.A., Mathijssen, R.H., De, B.P., 2003. J. Chromatogr. B
Analyt. Technol. Biomed. Life Sci. 795 (2), 383–388.
Edmond, G., Philippe, B., Lionel, M., Angelo, 2005. J. Pharma.
Biomed. Anal. 39 (3–4), 581–586.
Hang, W., Dutschman, G.E., Li, X., 2009. J. Chromatogr. B Analyt.
Technol. Biomed. Life Sci. 877 (27), 3038–3044.
Hwang, J.J., Marshall, J.L., Rizvi, N., 2003. Oncology 17 (Suppl. 5),
S46–S51.
ICH Guidance on Analytical Method Validation. In: Proc. Int.
Convention on Quality for the Pharmaceutical Industry, 2002;
Toronto, Canada.
Kawato, Y., Aonuma, M., Hirota, Y., Kuga, H., Sato, K., 1991.
Cancer Res. 51, 4187.
Kono, A., Hara, Y., 1991. Jpn. J. Cancer Chemother. 18, 2175–2178.
Murali, V., Balaram, J., Venkatashwara, R., RamaKrishna, S.,
Sankar, G., Balamurali, K.T., 2007. Eur. J. Chem 4, 128.
Owens, T.S., Dodds, H., Fricke, K., 2003. J. Chromatogr. B Analyt.
Technol. Biomed. Life Sci. 788 (1), 65–74.
Poujol, S., Pinguet, F., Malosse, F., Astre, C., Ychou, M., Culine, S.,
Bressolle, F., 2003. Clin. Chem. 49, 1900.
Rivory, L.P., Robert, J., 1994. J. Chromatogr. B Biomed. Appl. 661
(1), 133–141.
Sawada, S., Okajima, S., Aiyama, R., Nokota, K., Furuta, T.,
Yokokura, T., Sugini, E., Yamaguchi, K., Miyasaka, K., 1991.
Chem. Pharm. Bull. 39, 1446.
Shende, P., Gaud, R., 2009. Acta Chromatogr. 21 (1), 71–82.
Yang, X., Hu, Z., Chan, S.Y., Goh, B.C., Duan, W., Chan, E., Zhou,
S., 2005. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 821
(2), 221–228.
